[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

585-271-2700

Email address

JLeonard@vaccinex.com

Condition

Alzheimer Disease

Treatment type

Interventional

Investigational product

Pepinemab

Phase

Phase 1/Phase 2

Sponsor

Vaccinex Inc.

ClinicalTrials.gov identifier

NCT04381468

Study number

VX15/2503-11

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site